Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.56 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | GALR1 | P47211 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508966 | 0.91 | CYP4F2 (0.66) | CYP4F2CYP4A11MEP1BNPC1ALDH1A1 | |
| SCHEMBL5863216 | 0.90 | NPC1 (0.51) | CYP4F2CYP4A11NPC1ALDH1A1MAPT | |
| SCHEMBL4726691 | 0.90 | BCL2 (0.56) | CYP4F2CYP4A11MEP1BSMN1; SMN2 | |
| SCHEMBL29617015 | 0.87 | TP53 (0.62) | CYP4F2CYP4A11NPC1ALDH1A1MAPT | |
| SCHEMBL1996600 | 0.87 | CYP4F2 (0.61) | CYP4F2CYP4A11NPC1ALDH1A1MAPT | |
| SCHEMBL4193217 | 0.86 | TP53 (0.61) | CYP4F2CYP4A11TP53POLBHPGD | |
| SCHEMBL4447431 | 0.85 | LOXL2 (0.59) | CYP4F2CYP4A11NPC1ALDH1A1MAPT | |
| SCHEMBL30506526 | 0.85 | CYP4F2 (0.66) | CYP4F2CYP4A11 | |
| SCHEMBL17164349 | 0.85 | CYP4F2 (0.66) | CYP4F2CYP4A11 | |
| SCHEMBL5114415 | 0.85 | TP53 (0.49) | CYP4F2CYP4A11MEP1BNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960417-B2 | Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080312286-A1 | Indanone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-12-18 | — | — | US | disclosed |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | MERCK SHARP & DOHME CORP. | 2008-07-24 | — | — | US | disclosed |
| EP-1855670-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1773792-A1 | INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| WO-2006091496-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| WO-2006015158-A1 | INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312286-A1 | Indanone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRIK2, GRM1 | CYP4F2 2104/4885CYP4A11 3133/4885MEP1B 2719/4885 |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | GRM2, GRM3, GRIK2 | CYP4F2 1824/4885CYP4A11 3665/4885MEP1B 2242/4885 |
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | CYP4F2 3158/4885CYP4A11 1583/4885MEP1B 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.